Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06619990 · ClinicalTrials.gov registry record · Phase 1
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
A Phase 1 study of Ulcerative Colitis (UC), sponsored by Xencor.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT06619990: Recruiting Phase 1 study of Ulcerative Colitis (UC), sponsored by Xencor.
NCT06619990 is a Phase 1 study of Ulcerative Colitis (UC) that is actively recruiting participants, run by Xencor. The registered enrollment target is 270 participants, below the 749-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06619990, a Phase 1 study of Ulcerative Colitis (UC), is actively recruiting participants, sponsored by Xencor.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL XmAb942
Study Locations (20)
Florida
- Xencor Investigative Site - Bradenton
- Xencor Investigative Site - Jacksonville
- Xencor Investigative Site - Kissimmee
- Xencor Investigative Site - Tampa
Texas
- Xencor Investigative Site - Denton
- Xencor Investigative Site - Houston
- Xencor Investigative Site - Kingwood
- Xencor Investigative Site - San Antonio
Other
- Xencor Investigative Site - Sofia
- Xencor Investigative Site - Zagreb
- Xencor Investigative Site - Tbilisi
Western Australia
- Xencor Investigative Site - Joondalup
- Xencor Investigative Site - Nedlands
Ontario
- Xencor Investigative Site - London
- Xencor Investigative Site - Scarborough Village
Arizona
- Xencor Investigative Site - Scottsdale
North Carolina
- Xencor Investigative Site - Raleigh
New South Wales
- Xencor Investigative Site - Wollongong
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2029-01 |
| Phase | Phase 1 |
What NCT06619990 shows while recruiting
NCT06619990 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 749-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06619990 names 20 study sites across 10 states, led by Florida, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06619990 about?
NCT06619990 is a clinical study titled "Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis". Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).
What is the current status of trial NCT06619990?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 270 participants. The study started on 2024-10-10. Estimated completion is 2029-01.
What conditions does trial NCT06619990 study?
This clinical trial studies the following conditions: Ulcerative Colitis (UC).
What interventions are being tested in trial NCT06619990?
The interventions under investigation include: Placebo (DRUG), XmAb942 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06619990?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06619990 being conducted?
This trial has 20 study locations across Arizona, Florida, North Carolina, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis (UC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06619990's enrollment target sits among peer trials
270 5th of 17 higher than 13 of 17 other Ulcerative Colitis (UC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis (UC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
RECRUITING · Phase 1
-
Early Serum Infliximab Levels in Severe Ulcerative Colitis.
COMPLETED · Phase 1
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RECRUITING
-
Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
RECRUITING · Phase 2
-
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
RECRUITING · NA
-
Evaluation of the SMART IBD App in Pediatric IBD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI